Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of IMO-2055 with an intratumoral administration approach in combination with checkpoint kinase inhibitors in cancer patients

Next Previous
Trial Profile

Phase I/II trial of IMO-2055 with an intratumoral administration approach in combination with checkpoint kinase inhibitors in cancer patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMO 2055 (Primary) ; Checkpoint kinase inhibitors
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aceragen; Idera Pharmaceuticals

Most Recent Events

  • 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
  • 27 Mar 2015 New trial record
  • 12 Mar 2015 According to an Idera Pharmaceutical media release, data for at least one of the two phase I/II trials is expected to be available by end of 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top